HP-505 is a triple reuptake inhibitor that was investigated by Hoechst-Roussel Pharmaceuticals. In mice, HP-505 was a potent inhibitor of tetrabenazine-induced ptosis which may indicate antidepressant activity. Pharmacology + HP-505 IC50 (μM) 5-HT NE DA NE:5-HT DA:5-HT 0.19 ± 0.04 0.34 ± 0.1 0.66 ± 0.15 1.8 3.5 The inhibitory effect of HP-505 on serotonin reuptake is approximately 1.8 and 3.5 times stronger than on norepinephrine and dopamine, respectively. Subsequent investigations have found that HP-505 acts on presynaptic dopamine transporters and is devoid of anticholinergic effects. Synthesis The N-methylated analog is called HP-365 [59142-29-9].
An older synthesis is available, although more modern methods exist now:
References